Atherosclerosis is a chronic inflammatory arterial disease characterized by lipid-rich plaque buildup in vessel walls, leading to atherosclerotic cardiovascular disease. It underlies major events such as myocardial infarction, ischemic stroke, and peripheral arterial disease.
A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
mRNA medicine and spatiotemporal drug delivery systems are expanding options for cardiovascular disease. The sources describe preclinical proof-of-concept, clinical trials and programmable cardiac repair platforms.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07783802 |
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event |
NOT_YET_RECRUITING | PHASE2 |
| NCT07719894 |
Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes |
RECRUITING | PHASE4 |
| NCT07693712 |
Senescence in Myocardial Infarction |
TERMINATED | |
| NCT07625488 |
Measuring Athlete's Risk of Cardiovascular Events 3 (MARC-3) |
ENROLLING_BY_INVITATION | |
| NCT07614230 |
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes |
RECRUITING | PHASE4 |
| NCT07613294 |
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk |
RECRUITING | PHASE3 |
| NCT07611747 |
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) |
RECRUITING | PHASE4 |
| NCT07558239 |
Carotid Intima-media Thickness in Dialysis Patients and Traditional Risk Factors |
NOT_YET_RECRUITING | |
| NCT07545408 |
Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus |
NOT_YET_RECRUITING | |
| NCT07524101 |
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD |
RECRUITING | NA |
